Valuation : Biogen Inc.

Market Cap 32.63B 28.08B 26.42B 24.13B 45.14B 3,081B 45.27B 312B 121B 1,581B 123B 120B 5,092B P/E 2026 *
38.1x
P/E 2027 * 19.8x
Enterprise Value 37.57B 32.32B 30.41B 27.78B 51.97B 3,547B 52.11B 359B 139B 1,820B 141B 138B 5,862B EV / Sales 2026 *
3.6x
EV / Sales 2027 * 3.29x
Free-Float
85.8%
Yield 2026 *
-
Yield 2027 * -
1 day+3.77%
1 week+1.06%
Current month+0.97%
1 month+5.22%
3 months+14.63%
6 months+17.05%
Current year+26.66%
1 week 183.02
Extreme 183.02
194.12
1 month 175.9
Extreme 175.9
194.12
Current year 134.7
Extreme 134.7
194.12
1 year 115.65
Extreme 115.65
194.12
3 years 99
Extreme 99
255.4
5 years 99
Extreme 99
317.45
10 years 99
Extreme 99
351.7
Manager TitleAgeSince
Chief Executive Officer 66 13/11/2022
Director of Finance/CFO 60 28/02/2025
Chief Tech/Sci/R&D Officer - 27/10/2024
Director TitleAgeSince
Director/Board Member 69 22/03/2010
Director/Board Member 77 31/12/2009
Director/Board Member 72 18/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
+3.77%+1.06% - - 32.63B
-1.87%+4.22%+44.36%+0.58% 82.65B
-0.57%+1.27%-16.61%-35.57% 60.24B
-2.23%+5.48%+478.96%+33.09% 58.11B
-2.03%-2.62%-8.63%+27.87% 49.68B
-4.58%-2.73%+1.79%+159.87% 46.66B
-1.64%+1.07%+56.98%-17.07% 32.63B
-0.98%+1.91%+46.30%+100.30% 25.69B
-0.19%-4.74%-0.68%+194.68% 22.73B
-1.13%-2.45%+64.66%+108.24% 16.54B
Average -1.14%-0.24%+74.13%+63.55% 43.88B
Weighted average by Cap. -1.43%+0.74%+86.73%+42.82%

Financials

2026 *2027 *
Net sales 10.44B 8.99B 8.46B 7.72B 14.45B 986B 14.49B 99.92B 38.77B 506B 39.22B 38.36B 1,630B 10.66B 9.17B 8.63B 7.88B 14.74B 1,006B 14.78B 102B 39.56B 516B 40.01B 39.14B 1,663B
Net income 964M 829M 780M 713M 1.33B 91B 1.34B 9.22B 3.58B 46.69B 3.62B 3.54B 150B 1.86B 1.6B 1.5B 1.37B 2.57B 175B 2.57B 17.75B 6.89B 89.88B 6.97B 6.82B 290B
Net Debt 4.94B 4.25B 4B 3.65B 6.83B 466B 6.85B 47.23B 18.33B 239B 18.54B 18.13B 770B 2.42B 2.08B 1.96B 1.79B 3.35B 228B 3.36B 23.15B 8.98B 117B 9.09B 8.89B 378B
Logo Biogen Inc.
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (72%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (7.4%) ; - other (20.6%): primarily revenues from partnership agreements.
Employees
7,500
Date Price Change Volume
04/09/26 €189.92 +3.77% 125
02/09/26 €183.02 -1.80% 100
01/09/26 €186.38 -0.91% 584
31/08/26 €188.10 +0.10% 16
28/08/26 €187.92 -1.11% 28
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
220.83USD
Average target price
236.87USD
Spread / Average Target
+7.26%

Quarterly revenue - Rate of surprise